الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 213 |  |  |
| | | from | 213 | | |
Abstract
Behçet’s disease (BD) is a vasculitic and inflammatory disease which cause endothelial dysfunction. Irisin is a metabolic hormone associated with insulin resistance and endothelial dysfunction which was significantly correlated with carotid atherosclerosis.
Aim of the work: To evaluate the relationship between serum irisin and subclinical atherosclerosis in patients with Behçet’s disease and to compare serum irisin with other well modalities used to detect subclinical atherosclerosis and endothelial dysfunction.
Patients and methods: our patients are subjected to clinical examinations, Routine investigations (complete blood picture, erythrocyte sedimentation rate, liver and kidney functions, fasting blood glucose), lipogram, Measurement of serum irisin, Measurement of carotid artery intima-media thickness (CIMT) by Doppler ultrasound, Measurement of Ankle/Brachial blood pressure index and resting 12 leads ECG examination (measurement of Q-T dispersion).
Results: our results cleared that, the Serum Irisin level decreased in Behcet’s diseases group than the control group and the level of carotid intima-media thickness (CIMT) in Behcet’s disease is higher than its level in control group but ankle brachial pressure index in Behcet’s disease is lower than its level in control group so the level of Atherosclerosis incidences in Behcet’s disease higher than its incidences in control group.
Conclusion: Serum irisin levels in patients with BD had a negative relationship with CIMT, which is a well-known indicator for IR and subclinical atherosclerosis.
CONCLUSION
Our results concluded that: -
Subclinical atherosclerosis is detected by CIMT and ankle brachial index in patients with Behcet’s Disease.
Serum irisin levels in patients with BD has a negative relationship with CIMT, which is a well-known indicator for subclinical atherosclerosis so Low irisin levels in patients with BD can be associated with atherosclerosis so it can be used as a marker in Early Detection of Subclinical Atherosclerosis and Endothelial Dysfunction in Patients with Behcet’s Disease.
RECOMMENDATIONS
More studies are wanted to determine the role of serum irisin as a marker in early detection of subclinical atherosclerosis and endothelial dysfunction in patients with Behcet’s Disease and to determine the usefulness of irisin as adjunctive therapy in the management.